# Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2026

> **Open Intelligence Dossier** · First detected: 2026-06-26 15:07 UTC · Category: Business

## Executive Summary
The European Medicines Agency has issued a positive opinion recommending the approval of Eli Lilly's Jaypirca for chronic lymphocytic leukemia.

## Intelligence Brief
The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Jaypirca, also known as pirtobrutinib, for the treatment of adult patients with chronic lymphocytic leukemia (CLL). This recommendation covers the use of the medication across all lines of therapy.


Coverage from the European Medicines Agency, Yahoo Finance, and GuruFocus highlights the committee's decision during its June 22-25 meeting. Reports from Futu Securities note that the recommendation has prompted a submission for marketing authorization to the European Commission and resulted in stock market activity for Eli Lilly.


Future developments depend on the European Commission's final decision regarding the marketing authorization. Coverage does not yet specify a timeline for the final regulatory ruling.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| TIKR.com | Eli Lilly Stock Jumps 7% as Medicare Opens GLP-1 Access: What a $2,100 Target Means for Investors | [Source Link](https://news.google.com/rss/articles/CBMiuwFBVV95cUxNZER3U09sSkJNREc1RjNKeHFDLTZoY2ZHSmY5TktsS1hBLTdvUUtTT3RtZ1hub3NPRTVVVU1VZWZGVXlqQzFQS2NZSTUyaVhMejBTc1NSc25CNlZBM3VlTlJpRWk3bUJJLXl6bUktZXdEODh5VnItSXZ4YnF0RzB6YjZJSjZlczVVeEpzUGY3Yng4SGJGZGYtcDMyazY3NXlOWjE5WS1Zd3M0TkRKWklYaDYwblVpZnlHZjZF?oc=5) |
| Investor's Business Daily | Eli Lilly Leads 5 Stocks Near Buy Points As The Market Rally Rotates | [Source Link](https://news.google.com/rss/articles/CBMigwFBVV95cUxQVHhIQmtMM29iNmNXaVdEWHlZRW5mcVNKT3F5UFFKRVRFLVYzbnB4d0RtZm9DTFlGVU1kOEpreTZEejBiLThHbkxLQk5IVmR4U2RyWm81Vnc0OXpkdzRMZC1oLV9zZkV5amtleGVZbU9nX0FRNFhVX3FNbl9sRDliQlliYw?oc=5) |
| Yahoo Finance | Why Is Eli Lilly (LLY) Stock Soaring Today | [Source Link](https://news.google.com/rss/articles/CBMijAFBVV95cUxPWEFSdmxTaXgxejNjdFFwZkdoZkFFWlp0T0FSNnVHWFhHN1hTdnRLZEJzbzJNMi1kSXRRUDhOMzJmMHdfeGttWXRnQ1RUUUZDSnhtV0lKRU1TZTZCUUVGTy1lN2hCZnNkellGUklqVDVhZFlsODFqVGxhbTJBcDJNZXFPSXdYRm5QRkZQbg?oc=5) |
| Investor's Business Daily | Lilly Hits Record High On Massive Profit Growth, Leads 28 Just Added To Best Stock Lists | [Source Link](https://news.google.com/rss/articles/CBMiuwFBVV95cUxPVldDUWg4NlZSSFhsQ21WUVB0NzRPVnJTTnRXeVRqUl9EUGlNWUJjUDJmbGxkSjdkeDFHdzZBT09EeXdWYTE2TXJZazRYQTZhcDdScDI2NUI1UUVNY1RiSXo3VUxGSFYtZ1FlZXVBT1F2NmpINUpQZS1vRlV1eTg3MjF1YWExVUdUY2tuNmRuN2pIYks5RkQ3b0FQMGQ1akwtTEl5ZlpuUkVUUkZNN3FtNmNtSllRc2sxTzI4?oc=5) |
| Oncology News Central | Pirtobrutinib Plus Venetoclax Shows Promising Results in CLL | [Source Link](https://news.google.com/rss/articles/CBMitgFBVV95cUxOZFhBSHRianJGU3FLQU1RUjVLa1hKRmcyT01QcndWWWpRa2pWa0hBVVV6YUduQ0p3bl9nRlJOZFpXVmJYZ1dIRnBoSkVncFVmX3VJSkVoMFlndGhPRUgyd2U3enJuYmJHRmUxZm1WLWpPSktvdkhfb0hkRElYMkNfYVl0UFpOVmZreVFuYnRPM2lzbXAzR1BZS2NnSnZPYnJFRTItY3E2ZEdCbHZneWdPSHhKNy1zUQ?oc=5) |
| The Globe and Mail | Why Is Eli Lilly (LLY) Stock Soaring Today | [Source Link](https://news.google.com/rss/articles/CBMiwgFBVV95cUxNMUE4VmI1QVhydU52OEpKZVpINWNCQnFzeVYyWUhpZE5vSWU4UUktS2oteHBhUm1Kc2dZd3ZlMktkbkJoSUl6TzBZdmNNSVlyTVR5MW1YUXFjZzZDMlRzWE8zTnNjS1NqMERnWE1XV1RIQmV3MkRUQk5uN2hvTUI0LUk3WGd4aFhrSmtBV3lNb01YZGhHYkdycGFGV3NOTGVCeTl2NmNXZU9RYWZSdTVKZy1pbFpjb1QwbmFHQ3FPdTdaUQ?oc=5) |
| Yahoo Finance | Eli Lilly shares rise after EU panel backs expanded use of Jaypirca | [Source Link](https://news.google.com/rss/articles/CBMijgFBVV95cUxQV2Q3MmNBbDdDMWEtMzVPOVk5cmZjTHpJYlBVelhwTkVxbjBPYlVPLXBxX3diRkIwY0tjRGQ3Z2NJSnNYSndiZDktYnFLRXFOMXE5c0hjTkFjY054M29NbG41NW5kMl9uOUp4Zk9PZHp5LTc4cWZRWWltSGc3d1RMZVE1Y2xsUUNhSlkzMkl3?oc=5) |
| Oncodaily | Matthew Davids' Comments on the New Phase 3 Results From the BRUIN CLL-322 Trial - Dana-Farber | [Source Link](https://news.google.com/rss/articles/CBMiW0FVX3lxTFBsdmZpLWZoYWNVU3VzT2RpeGZFOGQ4ZFdUZTZLN3F3RFBuZ2huTC1rOEwyNUdVNWNnN3g0bEc1eHdESkhDd3I4QnVUUl95dTdhd1lwaUp3QnMwR3c?oc=5) |
| GuruFocus | Eli Lilly (LLY) Gains EMA Support for Cancer and Diabetes Treatm | [Source Link](https://news.google.com/rss/articles/CBMiqAFBVV95cUxPXzNxeWFCVy1kY0ozeWNReGFINk5TZlNWOGMtMk1SdmpBcWxQa3FlSDdaX2IwTjRvbXZKaV80RWFWZDVrcGtEM0oxdXlaMlZhOGoxdVZ6YmU5LW5GNXNEcTdfaXl3cFJSc2d3RDlmdDVLZEhIb1RsSjVES2pMVmE2YU5wakRWaWtCTUM3UEUxcElPa1FaeXFQcmJNbmU4dTh0OWlXc0RhV00?oc=5) |
| GuruFocus | Eli Lilly (LLY) Receives Positive EMA Opinion for Jaypirca Treat | [Source Link](https://news.google.com/rss/articles/CBMiqAFBVV95cUxNOFZpck44Q3RpTm1rbzhWV1BadkN1Sk4xYmNmODdrLVhpY1BYcVFtX1FOX05keTN2WWRUMkNLRF9OY1NoUzE4UURheG1NSzVIbWVLZXVndlpTdl8wcU5HQzhDaXFfTENyTEZtYTBRQ19wY3Bxb05JOXNGeGRGVGpjeEZFUkQ0cndoYVB0VmZWTzRPN0ZSbVQzbUJyLVo3OXpBRlhNTnA4LXo?oc=5) |
| Targeted Oncology | Dr Ahn: Exploring Treatment-Free Remissions With Pirtobrutinib in CLL | [Source Link](https://news.google.com/rss/articles/CBMiowFBVV95cUxOOUE2R2pfcXJmVTRGYTNGa0FCNTlJMm9kTk1ZS1MtbWg1UnN4Rlh6YVl4MlpEVEdrY2duRmpQcndDbTBkeGV1Yzh5QnRJeVRsYXJhMExVRXB3NVk1MG1LaWRFUm9aSUlFN3RKYnN3YUg3MDhLOGNSZGRQZVUzMjdWMFZqQUdNRUdqYnVWdmp5clpfdVZ0TjBEb0U4ai05SUZMRUdr?oc=5) |
| 富途牛牛 | U.S. Stocks Move - Eli Lilly and Co (LLY.US) Rises Over 4% as Jaypirca Marketing Authorization Application Submitted to European Commission | [Source Link](https://news.google.com/rss/articles/CBMikwFBVV95cUxQdGxpc1NXc1hPV3BmQkxkOEVSY1d1RzZ2SkE1cks1TEZXZnFnaWE1aERzbnkyWTg5NmtTcXM4NGJyaTlfdzM3b1d0WDVCS2FmWlBxcExVNE5qMEFHaldsQ0M0eUp5Q3FsLTU4MmZxRXlXRFpVS0pFMWY5cnJXbHpWY2ZmeVVjUjFOSG9kemQtTlMxRms?oc=5) |
| Yahoo Finance | Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy | [Source Link](https://news.google.com/rss/articles/CBMiqwFBVV95cUxPbnktZFZFb0lmN21wcU0zQUdROXV4SnBZV0NaMmNsOHJ5eDl2YktvTWlYdDZlRGNPQkNhaE90MDEzU2tRU1l4c1NxQkc2LU1mU096LXNJM1d4NWxkbmVKOWdua0N0Y0tQeGotejFBcnI2MGZUWll5a0dIX2diQzFTbXRwTWM3UGVhcDZuV1ZwTC1uMTI3b211Tm82QlhMSGlUN1hleC1JMzVKVTQ?oc=5) |
| European Medicines Agency (EMA) | Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2026 | [Source Link](https://news.google.com/rss/articles/CBMisgFBVV95cUxPZTZrNGcwTVBmQWtNNXl6UWJRandxMFRuNmFNTXVTT0lVeUVBQUI0a29FTG9NeHBaU0FBbE5sTFdYTDRQVXdob0F2NVBOZ1psUjNwLTJXTWNxeTlCSFVvMS1WYWF1WVNmZkJJWUxBa18wM2hiRWRJOHAtVWtoWWxELVBScmJxaDFla1FuWHFjcEc1MnRMLWpBLVZSOFd5b0RfZGpOV2dwdFp2d2xfcnFBLWpB?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-06-26/meeting-highlights-from-the-committee-for-medicinal-products-for-human-use-chmp*